Abstract:5688 CRM1 is an essential protein required to export a set of ‘cargo’ proteins which bear a leucine-rich nuclear export sequence (NES) from the nucleus to the cytoplasm. Examples of cancer-related proteins bearing CRM1-dependent NESs include p53, BCR-Abl, and FOXO-3a. Nuclear sequestration of these CRM1 ‘cargo’ proteins upon inhibition of CRM1 can lead to cell growth inhibition in normal cells or apoptosis in cancer cells. The identification of CRM1 as a novel target in cancer came from the study of Leptomycin B (LMB) and its analogs. These molecules are potent cytotoxic agents which belong to a group of polyketide natural products known as nuclear export inhibitors (NEIs). LMB and its analogs covalently bind to the nuclear exportin CRM1 and thereby inhibit its ability to shuttle cargo proteins to the cytoplasm. The development of LMB was limited by the significant toxicity observed in previous studies (Newlands, et al., 1996, Br. J. Can., 74: 648-649). We have recently developed a series of NEI analogs with significantly improved biological and pharmacological properties over LMB. Upon examination of the activity of these molecules in leukemia cell lines, we found that NEIs were very potent in vitro in ALL (Molt-4, CCRF-CEM, Jurkat) and AML (MV-4-11) cell lines. Exposure to NEIs led to a rapid and dramatic induction of multiple markers of apoptosis (caspases, Annexin V binding). Based on these results, we examined the activity of two NEI analogs, KOS-1815 and KOS-2464, in murine leukemia xenograft models. Both of these drugs, when dosed on a weekly schedule, significantly inhibited the growth of MV-4-11 (T/C = ~22% for KOS-2464 and ~26% for KOS-1815) and Molt-4 (T/C = ~38% for KOS-2464 and ~29% for KOS-1815) xenografts. In addition, a single administration of KOS-2464 or KOS-1815 induced regression of large (>1000 mm3) CCRF-CEM xenografts. KOS-2464 was very well-tolerated at efficacious doses in all of these leukemia models, while KOS-1815 induced a ~5 to 10% transient body weight loss upon dosing. Finally, we established a Molt-4 orthotopic leukemia model in mice. Weekly dosing of KOS-1815 and KOS-2464 for three weeks, beginning eight days after cancer cell implantation, doubled survival of these leukemic mice. Median survival increased from 25 days for the control group to 50+ days for the drug-treated groups (56 days for KOS-2464 and 50 days for KOS-1815). Studies are ongoing to gain further insight into the mechanism by which these molecules exert their activity in leukemia models. Taken together, the current study shows that KOS-2464, our lead NEI analog, with its novel mechanism of action and wide therapeutic window, has significant potential as a novel anti-cancer agent, especially for the treatment of leukemia.

Nitroxoline shows antimyeloma activity by targeting the TRIM25/p53 axle.

Nitroxoline induces cell apoptosis by inducing MDM2 degradation in small-cell lung cancer

Triptolide Inhibits Transcription Factor Nf-Kappab and Induces Apoptosis of Multiple Myeloma Cells

Quercetin induces cell apoptosis of myeloma and displays a synergistic effect with dexamethasone in vitro and in vivo xenograft models.

Targeting ABCB6 with nitidine chloride inhibits PI3K/AKT signaling pathway to promote ferroptosis in multiple myeloma

Novel Conjugates of Endoperoxide and 4-Anilinoquinazoline Induce Myeloma Cell Apoptosis by Inhibiting the IGF1-R/AKT/mTOR Signaling Pathway.

Polyphyllin I Induces Cell Cycle Arrest and Apoptosis in Human Myeloma Cells Via Modulating Β‐catenin Signaling Pathway

A novel 2-iminobenzimidazole compound, XYA1353, displays in vitro and in vivo anti-myeloma activity via targeting NF-κB signaling

Synthesis And Biological Evaluation Of 3-Aryl-Quinoxaline-2-Carbonitrile 1,4-Di-N-Oxide Derivatives As Hypoxic Selective Anti-Tumor Agents

A Inhibits Multiple Myeloma Cell Growth Through Induction 53-Mediated Caspase-Dependent Apoptosis and Ergistically Enhances Nutlin-Induced

A novel phosphoramide compound, DCZ0805, shows potent anti-myeloma activity via the NF-κB pathway

Hypoxia-selective cytotoxicity and radiosensitization of quinoxaline 1,4-di-N-oxide derivative, QN-2013

Preclinical Activity Of Dcz3301, A Novel Aryl-Guanidino Compound In The Therapy Of Multiple Myeloma

5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma

A Novel Quinolinylmethyl Substituted Ethylenediamine Compound Exerts Anti-Cancer Effects Via Stimulating the Accumulation of Reactive Oxygen Species and NO in Hepatocellular Carcinoma Cells.

A 1,2,3-Triazole Derivative of Quinazoline Exhibits Antitumor Activity by Tethering RNF168 to SQSTM1/P62

Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells

Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.

A Novel Small Molecule Agent Displays Potent Anti-Myeloma Activity by Inhibiting the JAK2-STAT3 Signaling Pathway.

Anti-tumor Activity of Novel Nuclear Export Inhibitors (neis) in Multiple Murine Leukemia Models

Augmented Concentration of Isopentyl-Deoxynyboquinone in Tumors Selectively Kills NAD(P)H Quinone Oxidoreductase 1-Positive Cancer Cells through Programmed Necrotic and Apoptotic Mechanisms